Global Migraine Drugs Market is Expected to Reach a Market Value of USD 3.71 Billion by 2025

Migraine drugs market is estimated to grow at 3.5% for 2018-2025 with factors such as lack of proper diagnosis along with adverse effects of drugs which will hamper the growth of the market in emerging economies.

Migraine drugs market has shown an exceptional penetration in developed economies in North America. Increasing occurrences of novel therapeutics and growing population which will help in driving the growth of the market.

Migraine Drugs Market Scenario

According to Data Bridge Market Research the migraine drugs market is witnessing a significant growth in developing economies during the forecast period of 2018-2025 due to factors such as rising health awareness among the people along with prevalence of migraines, tentative approval of pipeline candidates which will help in boosting the growth of the market.

Now the question is which are the other regions that migraine drugs market is targeting? Data Bridge Market Research has estimated a large growth in Asia-Pacific migraine drugs market in the forecast period of 2018-2025. The Data bridge market research new reports highlight the major growth factors and opportunities in the migraine drugs market.

For more analysis on the migraine drugs market request for a briefing with our analysts

Migraine Drugs Market Development in 2020

  • In January 2020, Eli Lilly's Emgality announced the launch of CGRP class of migraine prevention drugs which will offer relief within two hours and available at an affordable price.

Scope of the Migraine Drugs Market

Migraine drugs market is segmented on the basis of countries into U.S., Canada, Mexico in North America, Brazil, Argentina, Rest of South America as a part of South America, Germany, France, U.K., Italy, Spain, Netherlands, Belgium, Russia, Turkey, Switzerland, Rest of Europe in Europe, China, Japan, India, Australia, Singapore, Thailand, Malaysia, South Korea, Indonesia, Philippines, Rest of Asia-Pacific (APAC) as a part of Asia-Pacific (APAC), U.A.E, Egypt, Saudi Arabia, South Africa, Israel,  Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

  • All country based analysis of the migraine drugs market is further analyzed based on maximum granularity into further segmentation. On the basis of available treatments, the market is segmented into abortive treatment, and prophylactic treatment. Based on route of administration, the market is segmented into injectable, oral, and others.  
  • Migraines are severe, incapacitating headaches in one side of the human head, with intense throbbing or pulsing with symptoms include sensitivity to light, sound, smell, visual disturbances such as auras and nausea or vomiting. They are more painful than regular headache which can affect an individual's daily life.  

To know more about the study

Key Pointers Covered in the Migraine Drugs Market Industry Trends and Forecast to 2025

  • Market Size
  • Market New Sales Volumes
  • Market Replacement Sales Volumes
  • Market Installed Base
  • Market By Brands
  • Market Procedure Volumes
  • Market Product Price Analysis
  • Market Healthcare Outcomes
  • Market Cost of Care Analysis
  • Market Regulatory Framework and Changes
  • Market Prices and Reimbursement Analysis
  • Market Shares in Different Regions
  • Recent Developments for Market Competitors
  • Market Upcoming Applications
  • Market Innovators Study

Key Market Competitors Covered in the report

  • Abbott
  • Aegis Theraputics, LLC
  • Aerial BioPharma LLC.
  • Alder BioPharmaceuticals Inc.
  • Amgen Inc.
  • Astellas Pharma India Private Limited
  • AstraZeneca
  • Dr. Reddy’s Laboratories Ltd.
  • Johnson & Johnson Services, Inc
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Bayer AG
  • CoLucid
  • KOWA Pharmaceuticals America, Inc.
  • Luitpold Pharmaceuticals, Inc.
  • Klaria
  • Ethypharm
  • Global Information, Inc.
  • LePro PharmaCompass OPC Private Limited
  • Zogenix, Inc.
  • Bausch Health Companies Inc.
  • TG Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd
  • Horizon Pharma plc.
  • Aralez Pharmaceuticals Inc.
  • RedHill
  • Pfizer Inc
  • OptiNose US, Inc
  • Merck & Co.
  • Suda Ltd.

Above are the key players covered in the report, to know about more and exhaustive list of Migraine Drugs companies contact us

Research Methodology: Global Migraine Drugs Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

  • Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.
  • Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Related Reports

Browse in Healthcare Category Related Reports@